Wall Street’s latest AI conversation is becoming less about clever chatbots and more about the decidedly unglamorous work of power, chips, networks, security and uptime. That shift may be constructive for investors: it broadens the AI opportunity from a small club of…
Palantir Technologies Inc. (NASDAQ: PLTR) is advancing a distinctly bullish proposition for the AI economy: the winners will not merely own the largest models or the most GPUs; they will retain control of the proprietary operating knowledge that makes their businesses valuable in…
McDonald’s Corp. (NYSE: MCD), Similarweb Ltd. (NYSE: SMWB), and Amwell (NYSE: AMWL) are pursuing distinctly different strategies, but their direction points to one increasingly investable conclusion: companies that own meaningful customer interactions are finding new ways to monetize the data, workflow and…
Parkinson’s disease is one of medicine’s most stubborn commercial and scientific frontiers, and Serina Therapeutics, Inc. (NYSE American: SER) is positioning its lead program, SER-252, squarely in the middle of that opportunity. The clinical-stage biotechnology company has opened registration for a Tribe Public CEO…
Serina Therapeutics, Inc. (NYSE American: SER) is approaching a consequential clinical milestone with SER-252, its long-acting POZ-apomorphine candidate for advanced Parkinson’s disease, now advancing into Cohort 2 of a registrational Phase 1b study. For many, the appeal is not simply that Serina is pursuing…
In an era when nearly every company can publish a deck, record a webcast and summon an algorithmic audience, the scarce asset is becoming more human: a room, or a virtual room, filled with people who actually care enough to listen, ask…
Knightscope (NASDAQ: KSCP) is pursuing a bigger prize than selling robots: it is assembling an integrated, technology-enabled security service designed to combine autonomous machines, AI software, remote monitoring and licensed human agents under one accountable operating model.
There is no shortage of…
Serina Therapeutics, Inc. (NYSE American: SER) is building a potentially compelling clinical and platform-driven story around a familiar biotech proposition: take a medicine with demonstrated utility, improve the way it behaves in the body, and create a product patients may find meaningfully…
Knightscope, Inc. (NASDAQ: KSCP) is making a broader case than “robots on patrol.” With record second-quarter revenue, an expanding national client base, new AI-driven security capabilities and an integrated model that joins autonomous machines with trained human professionals, the company is positioning itself…
NVIDIA Corp. (NASDAQ: NVDA) has spent the past several years selling the shovels for the artificial-intelligence gold rush. Its planned $12.93 billion acquisition of Hugging Face suggests it now wants a more influential place in the mine, the marketplace and perhaps the…
